Status:
UNKNOWN
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients
Lead Sponsor:
Diskapi Teaching and Research Hospital
Conditions:
Fibroblast
Eligibility:
All Genders
18+ years
Brief Summary
Serum FGF-23 levels will be measured in patients with a history of coronary artery disease and aortic valve calcifications.It will be searched whether patients with MPI\>0.47 had higher or lower serum...
Detailed Description
Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mort...
Eligibility Criteria
Inclusion
- Adult hemodialysis patients (age\>18 years old)
Exclusion
- Malignancy, active infection
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT01154842
Start Date
December 1 2009
End Date
June 1 2010
Last Update
July 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diskapi Training and Research Hospital
Ankara, Turkey (Türkiye)